Skip to Main Content

Money has gushed into the biotech industry over the last couple of years, as the pandemic brought the industry onto center stage. At the same time, tech investors have rushed into the arena.

Who has benefited the most?


STAT analyzed yearly financial records from more than four dozen biotech investment firms that laid out their assets, both in liquid cash and also biotech stock portfolios, to determine which have seen the most growth over time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.